Investor Relations

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies for neuropathic pain. The Company has received marketing approvals in the U.S. and E.U. for Qutenza®, a synthetic capsaicin-based dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is expected to launch in 2010 in Europe by the Company’s commercialization partner Astellas Pharma Europe Ltd. and in the U.S. by NeurogesX’ own specialty sales force targeting pain specialists.

The Company’s development pipeline currently includes NGX-1998, a dermal, high-concentration liquid formulation of capsaicin designed to provide rapid, localized and sustained pain relief to treat peripheral neuropathic pain conditions, particularly in areas of the skin where a patch application may not be suitable. The company has also conducted preclinical evaluations for opioid prodrug and analgesic prodrug programs for managing additional chronic and acute pain conditions.